BIOADAPTIVES INC

For the period ended Dec 31, 2023. Filed Apr 10, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 10, 2024

BDPTStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheet

	December 31,	December 31,
	2023	2022
ASSETS
Current Assets:
Cash	$60,776	$25,405
Marketable securities	-	42
Inventory	15,281	8,877
Security deposit	2,500
Prepaid expense	10,000	-
Total Current Assets	88,557	34,324
License and patent, net	15,441	2,990
TOTAL ASSETS	$103,998	$37,314
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Accounts payable and accrued liabilities	443,579	409,920
Derivative liabilities	977,872	686,856
Current portion of convertible notes - net of discount of $52,592 and $7,647	321,658	381,793
Note payable - related party	7,520	10,246
Total Current Liabilities	1,750,629	1,488,815
Total Liabilities	1,750,629	1,488,815
Stockholders’ Deficit:
Preferred stock, ($0.0001 par value, 10,000,000 shares authorized;
Series A Preferred Stock 4,000,000 shares designated; 2,850,000 and 1,600,000 issued and outstanding, respectively	285	160
Series B Preferred Stock 5,000,000 shares designated; 2,250,000 and 0 share issued and outstanding, respectively	225	-
Common stock ($0.0001 par value, 1,250,000,000 shares authorized; 895,760,225 and 252,554,765 shares issued and outstanding, and 10,000 issuable, respectively)	89,576	25,255
Additional paid-in capital	6,527,428	6,074,763
Accumulated deficit	(8,264,145)	(7,551,679)
Total Stockholders’ Deficit	(1,646,631)	(1,451,501)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$103,998	$37,314

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.